Diagnostics Pipeline: Cizzle Bio Introduces Test for Earlier Lung Cancer Detection
The CIZ1B biomarker blood-based assay has 95% sensitivity for detecting earliest stage of the cancer
The CIZ1B biomarker blood-based assay has 95% sensitivity for detecting earliest stage of the cancer
From – Diagnostic Testing & Emerging Technologies
In what has been called the “era of the medical selfie,” at-home, smartphone-based urine testing is now a reality. In a short timeframe, the…
From – Diagnostic Testing & Emerging Technologies
A novel fingerstick test may improve access to Toxoplasma gondii testing for pregnant women, according to…
From – Diagnostic Testing & Emerging Technologies
Artificial intelligence- (AI-) based technology is beginning to penetrate health care. Like most other clinical decision-making, several early AI applications rely upon…
From – Diagnostic Testing & Emerging Technologies
A group of blood metabolites help detect some children with autism spectrum disorder (ASD), according to a study published…
From – Diagnostic Testing & Emerging Technologies
Preimplantation genetic testing for aneuploidy (PGT-A) can mitigate the negative effects of maternal age on in vitro fertilization (IVF) outcomes by…
From – Diagnostic Testing & Emerging Technologies
“Invisible” blood in stool may predict death from a wide range of causes, not just colorectal cancer, according to a study published July 16 in…